ArticleJournal of proteome research2026
UltraPlex-TMT: Expanding Isobaric Hyperplexing via Orthogonal Protease Cleavage.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isobaric labeling is widely used in quantitative proteomics for its multiplexing capabilities, but scaling beyond current limits remains a challenge. Here, we introduce UltraPlex-TMT, a streamlined and scalable workflow that integrates orthogonal protease digestion with hyperplex TMT/TMTpro labeling to effectively double sample throughput. UltraPlex-TMT can be readily implemented without custom chemistry or instrumentation. We benchmarked UltraPlex-TMT using lysine- and arginine-specific protease digests of a two-species proteome labeled with TMT11plex and TMT18plex across four subplexes in a proof-of-concept pseudo-58-plex design. MS2 acquisition quantified ∼6,000-7,000 proteins per subplex and ∼9,000 in total, with ∼50% overlap across all conditions, generating a robust core proteome set with high quantitative reproducibility. RTS-MS3 acquisition showed similar coverage trends, albeit with fewer quantified proteins. Despite reduced depth, MS3 data provided higher quantification accuracy, illustrating a trade-off between proteome depth and precision. Gene set enrichment analysis revealed strong biological concordance between MS2 and MS3 data, and in all conditions tested, the use of orthogonal protease digestion did not introduce systematic quantification bias. UltraPlex-TMT offers a flexible foundation for isobaric labeling-based high-throughput proteomics and is poised to benefit from faster acquisition platforms and extended multiplexing chemistries, supporting future studies exceeding 200-plex scale, potentially equivalent to subminute analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.